Clinical Trial on Agitation in Alzheimer's Dementia

IGC-AD1 is being tested in a difficult CNS indication: agitation in Alzheimer's dementia. The study does have a placebo control and a direct symptomatic endpoint, and CMAI is a standard agitation scale, so a signal is measurable within six weeks if the drug truly works. But the setup still looks below coin flip. The population spans mild to severe disease, which adds heterogeneity and can dilute treatment effect. Behavioral endpoints such as CMAI are clinically relevant yet noisy, caregiver- and site-sensitive, and vulnerable to placebo response. A THC-based drug could reduce agitation through sedation, but in frail dementia patients that same pharmacology can also limit tolerated dosing and create dropouts or confounding adverse effects. Operationally, the trial is still listed as recruiting even though the estimated primary completion date has just passed, which raises risk around enrollment pace, data maturity, and clean disclosure timing. Overall, this looks like a real but modest chance of a positive readout, not a likely winner.

The CALMA Phase 2 trial is far from producing final results. As of February 2026, only ~70% of patients were enrolled, with full enrollment expected by mid-2026. The estimated primary completion date (March 30, 2026) has passed without any results disclosed. Interim data from just 26 of 146 patients showed a promising CMAI difference of -10.45 (p=0.037), but this tiny sample is highly susceptible to regression to the mean in the full dataset. CNS behavioral endpoints notoriously exhibit large placebo responses, and THC-based therapies face blinding challenges (psychoactive effects may unblind participants). IGC Pharma is a micro-cap company ($0.30/share capital raises) with limited clinical development experience. The base rate for Phase 2 CNS trials hitting primary endpoints is roughly 30-35%. While interim signal is encouraging, the wide confidence interval (-20.20 to -0.72) and small n suggest fragility. Additionally, results may not be available for months, adding resolution timing risk. Overall probability of positive final results is below 50%.

This Phase 2 trial tests IGC-AD1, a THC-based oral formulation for agitation in Alzheimer's dementia. The primary endpoint (CMAI change over 6 weeks) is a validated measure. However, several factors reduce confidence: (1) Phase 2 trials have high failure rates (~67%); (2) THC-based drugs face regulatory scrutiny and variable patient response; (3) The sponsor (IGC) is a small company with limited resources; (4) The trial status shows 'Recruiting' despite primary completion being 3 days past estimated date, suggesting possible enrollment or data collection challenges. The mechanism (THC for neuropsychiatric symptoms) has biological plausibility but mixed prior evidence in dementia. Given these counterbalancing factors, intrinsic YES probability is modestly below even odds.

The trial is a small Phase 2 study in a difficult indication. While agitation in Alzheimer's is a high unmet need, the intervention is a THC-based formulation, which has a mixed prior record in neuropsychiatric symptoms. The primary endpoint uses the established CMAI scale, which is a positive. Key risks include the small sponsor (IGC Pharma), the inherent variability of behavioral endpoints, and the challenge of demonstrating a clear signal over placebo in a complex patient population. The trial status is 'Recruiting' but the primary completion date has passed, suggesting possible delays in data readout. Overall, the probability of a clear positive result is below even odds.

Phase 2 trial of THC-based IGC-AD1 (oral BID) vs placebo in mild-to-severe Alzheimer's dementia patients with agitation. Primary endpoint—change in CMAI score (baseline to week 6)—is validated, multi-item observer scale capturing physical/vocal agitation, suitable for dementia. Population appropriate but broad severity range risks heterogeneity and diluted signal. Alzheimer's agitation trials plagued by high placebo response (30-50%), behavioral variability, and low Phase 2 success (~25% in neuro psych). No prior efficacy data in fields; cannabinoid anxiolysis plausible but lacks robust RCT support here. Small sponsor (IGC Pharma) heightens execution risk: status 'Recruiting' despite primary completion overdue (-3 days) flags enrollment/operational delays. Short 6-week duration may hinder statistical separation. Disclosure risk elevated near overdue date, potential for interim negatives. Endpoint strength offset by indication challenge, sponsor weakness yields ~30% YES probability.

This Phase 2 trial (NCT05543681) tests IGC-AD1, a low-dose THC formulation, for Alzheimer's agitation. While THC has sedative properties that could theoretically reduce agitation, the evidence base for cannabis-based medicines in dementia is weak. Critically, the trial's primary endpoint measures change on the Cohen-Mansfield Agitation Inventory (CMAI), a subjective caregiver rating scale. The primary completion date has passed (March 2026), but the status remains 'Recruiting' with no results posted. This suggests potential delays or inconclusive results. Given the high failure rate of psychiatric interventions in dementia and the lack of historical efficacy for this specific formulation, the probability of a clearly positive outcome is estimated at 35%.

Phase 2 Alzheimer's agitation trials face substantial hurdles. The CMAI endpoint is validated but highly variable, and THC-based interventions carry cognitive side-effect risks that may obscure efficacy signals. Primary completion was 3 days ago with status still 'Recruiting,' suggesting data unblinding and analysis remain pending—typical timeline lag is 2-6 months. Sponsor IGC Pharma is micro-cap with limited Phase 2 track record. Prior cannabis-based Alzheimer's studies (Sativex, synthetic THC) showed mixed results with modest effect sizes. The 6-week treatment duration is short for neuropsychiatric symptom assessment. No interim data or DSMB disclosures have emerged, which is neutral but doesn't signal early stopping for efficacy. Disclosure risk is elevated given micro-cap structure and retail investor base. Overall, intrinsic probability of positive results is below 50% due to mechanistic uncertainty, endpoint variability, and sponsor execution risk.

IGC Pharma is evaluating IGC-AD1 (THC and melatonin) for Alzheimer's agitation. While they tout positive interim results, a closer look reveals the reported p-value of 0.037 on the CMAI was achieved by combining week two and week six results. Since the primary endpoint is strictly the change from baseline to week 6, this post-hoc pooling strongly suggests the week 6 timepoint alone lacked statistical significance in the interim cut. Alzheimer's agitation is a notoriously difficult indication plagued by high and durable placebo responses, which typically strengthen over a 6-week period. Furthermore, the trial has faced highly protracted enrollment, taking over three years to reach just 70% of 164 planned patients as of February 2026. Such delays frequently correlate with operational challenges, trial fatigue, or elevated dropout rates. Given the sponsor's micro-cap status, reliance on retail-focused promotion, and the questionable statistical parsing of early data, the likelihood of a clean, statistically significant success on the formal week 6 primary endpoint is poor. The market's 49% YES price fundamentally misprices these deep structural and statistical red flags.

The trial is in Phase 2, which has a relatively high failure rate. The primary endpoint is focused on agitation in Alzheimer's patients, which is a complex and subjective measure. While the intervention is a THC-based formulation, which has shown promise in some studies, the sample size and study design may not be sufficient to conclusively demonstrate efficacy. Additionally, the study's primary completion date was recently passed, which may indicate potential delays or issues with patient recruitment or data collection.